Non Small Cell Lung Cancer Clinical Trials in Atlanta, Georgia

20 studies are recruiting for non small cell lung cancer in Atlanta, Georgia right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

    The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the first-line (1L) treatment of patients with locally advanced or metastatic squamous non-small cell lung cancer (mNSCLC) whose tumors express programmed death-l…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Research Site, Atlanta, Georgia
    Locations
    328 in total
    Run by
    AstraZeneca

    See if you can join NCT06692738 on ClinicalTrials.gov

  2. Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

    Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Clinical Study Site, Atlanta, Georgia
    Locations
    285 in total
    Run by
    Summit Therapeutics

    See if you can join NCT06767514 on ClinicalTrials.gov

  3. A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

    This study will assess if adding sacituzumab tirumotecan with pembrolizumab after surgery is effective in treating NSCLC for participants not achieving pathological complete response. The primary hypothesis of this study is sacituzumab tirumotecan plus pembrolizumab is superior to pembrolizumab mon…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Piedmont Atlanta Hospital ( Site 4000), Atlanta, Georgia
    Locations
    269 in total
    Run by
    Merck Sharp & Dohme LLC

    See if you can join NCT06312137 on ClinicalTrials.gov

  4. Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

    Beamion LUNG-3 study evaluates whether zongertinib, an oral HER2-targeted treatment, can improve outcomes compared with standard adjuvant treatment in adults with completely resected Stage II-IIIB non-small cell lung cancer (NSCLC) whose tumors have activating HER2 tyrosine kinase domain (TKD) muta…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Piedmont Cancer Institute, Atlanta, Georgia
    Locations
    202 in total
    Run by
    Boehringer Ingelheim

    See if you can join NCT07195695 on ClinicalTrials.gov

  5. A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer

    This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab in patients with metastatic KRAS G12D - mutated Non-Small Cell Lung Cancer

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Emory Winship Cancer Institute, Atlanta, Georgia
    Locations
    13 in total
    Run by
    Verastem, Inc.

    See if you can join NCT07659782 on ClinicalTrials.gov

  6. Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer

    This clinical trial is designed to assess the efficacy and safety of trastuzumab deruxtecan (T-DXd; Enhertu®) in combination with pembrolizumab versus platinum-based chemotherapy in combination with pembrolizumab in participants with no prior therapy for locally advanced unresectable or metastatic …

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Piedmont Cancer Institute OneOncology, Atlanta, Georgia
    Locations
    242 in total
    Run by
    Daiichi Sankyo

    See if you can join NCT06899126 on ClinicalTrials.gov

  7. FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC

    The purpose of this multicenter, open label trial (NAPISTAR 1-01) is to evaluate the safety/tolerability, pharmacokinetics and preliminary efficacy of TUB-040 and to find the best dose of TUB-040 in participants with ovarian cancer and Non Small Cell Lung Cancer. TUB-040 is an antibody-drug-conjuga…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Emory University, Atlanta, Georgia
    Locations
    29 in total
    Run by
    Tubulis GmbH

    See if you can join NCT06303505 on ClinicalTrials.gov

  8. A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)

    The main purpose of this study is to evaluate the efficacy of divarasib compared with investigator's choice of immunotherapy (pembrolizumab or nivolumab) or observation in participants with resected Kirsten rat sarcoma viral oncogene homolog glycine 12 to cysteine (KRAS G12C)-positive Stage II-IIIB…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Piedmont Cancer Institute, PC, Atlanta, Georgia
    Locations
    19 in total
    Run by
    Hoffmann-La Roche

    See if you can join NCT07541170 on ClinicalTrials.gov

  9. A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

    The purpose of this study is to evaluate the efficacy and safety of divarasib and pembrolizumab compared with pembrolizumab and pemetrexed and carboplatin or cisplatin, for the first-line treatment of adult participants with KRAS G12C-mutated, advanced or metastatic non squamous non-small cell lung…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Piedmont Cancer Institute, PC, Atlanta, Georgia
    Locations
    280 in total
    Run by
    Hoffmann-La Roche

    See if you can join NCT06793215 on ClinicalTrials.gov

  10. Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

    The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to docetaxel.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Piedmont Healthcare, Inc, Atlanta, Georgia
    Locations
    153 in total
    Run by
    Revolution Medicines, Inc.

    See if you can join NCT06881784 on ClinicalTrials.gov

  11. Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC

    Multicenter, randomized, controlled, open-label, Phase 3 study designed to demonstrate that neladalkib (NVL-655) is superior to alectinib in prolonging progression-free survival (PFS) in patients with treatment-naïve, Anaplastic Lymphoma Kinase (ALK) positive, advanced Non-Small Cell Lung Cancer (N…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Winship Cancer Institute of Emory University, Atlanta, Georgia
    Locations
    158 in total
    Run by
    Nuvalent Inc.

    See if you can join NCT06765109 on ClinicalTrials.gov

  12. Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

    A Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after failure of EGFR TKI Therapy

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Piedmont Healthcare, Atlanta, Georgia
    Locations
    186 in total
    Run by
    Bristol-Myers Squibb

    See if you can join NCT07100080 on ClinicalTrials.gov

  13. MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

    The main purpose of this study is to assess safety \& tolerability and antitumor activity of LY3962673 as monotherapy and in combination with other chemotherapy agents in participants with KRAS G12D-mutant advanced solid tumor types. The study is expected to last approximately 5 years.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Emory University School of Medicine, Atlanta, Georgia
    Locations
    52 in total
    Run by
    Eli Lilly and Company

    See if you can join NCT06586515 on ClinicalTrials.gov

  14. Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

    The purpose of this study is to evaluate efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegostomig monotherapy compared with pembrolizumab monotherapy as a first line therapy in participants with locally advanced or metastatic non-squamous NSCLC with high PD-L1 expression (…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Research Site, Atlanta, Georgia
    Locations
    287 in total
    Run by
    AstraZeneca

    See if you can join NCT06357533 on ClinicalTrials.gov

  15. Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

    This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizuma…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Winship Cancer Institute - Emory University, Atlanta, Georgia
    Locations
    42 in total
    Run by
    Inhibrx Biosciences, Inc

    See if you can join NCT04198766 on ClinicalTrials.gov

  16. Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

    This is a phase 1/2, multicenter, open-label study. The phase 1 portion is a dose escalation and expansion study of STK-012 as monotherapy and in combination therapy in patients with selected advanced solid tumors. The phase 2 portion is a randomized study of STK-012 in combination with standard of…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Winship Cancer Institute, Emory University, Atlanta, Georgia
    Locations
    47 in total
    Run by
    Synthekine

    See if you can join NCT05098132 on ClinicalTrials.gov

  17. A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)

    This is a Phase II, multi-center, open-label platform study evaluating novel combination treatment options in participants with locally advanced or metastatic NSCLC. The study will consist of several sub-studies, each evaluating the safety, tolerability, and preliminary antitumour activity of vario…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Research Site, Atlanta, Georgia
    Locations
    83 in total
    Run by
    AstraZeneca

    See if you can join NCT07098338 on ClinicalTrials.gov

  18. A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors

    Genes contain genetic code which tell the body which proteins to make. Many types of cancer are caused by changes, or mutations, in a gene called KRAS. Researchers are looking for ways to stop the actions of abnormal proteins made from the mutated KRAS gene. ASP5834 is being studied in people with …

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Winship Cancer Institute at Emory University, Atlanta, Georgia
    Locations
    20 in total
    Run by
    Astellas Pharma Inc

    See if you can join NCT07094204 on ClinicalTrials.gov

  19. GEMINI-NSCLC: NSCLC Biomarker Study

    GEMINI NSCLC Study is a non-interventional study that will be collecting clinical and molecular health information from patients with NSCLC who will receive longitudinal blood collection in addition to their standard of care therapy and disease surveillance with the goals of identifying the molecul…

    Stage
    Not phased
    Ages
    18 and older
    Site
    Morehouse School of Medicine (MSM), Atlanta, Georgia
    Locations
    58 in total
    Run by
    Tempus AI

    See if you can join NCT05236114 on ClinicalTrials.gov

  20. SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

    International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical…

    Stage
    Not phased
    Ages
    Any age
    Site
    Massive Bio SYNERGY-AI site, Atlanta, Georgia
    Locations
    68 in total
    Run by
    Massive Bio, Inc.

    See if you can join NCT03452774 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.